Page last updated: 2024-11-12

pyrostatin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyrostatin A: inhibits N-acetyl-beta-D-glucosaminidase; isolated from Streptomyces; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-hydroxyectoine : A carboxamidine heterocycle which is obtained by formal condensation of 4-amino-L-allothreonine with acetic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12011795
CHEMBL ID1230488
CHEBI ID49432
SCHEMBL ID748472
SCHEMBL ID15281462
MeSH IDM0249527

Synonyms (36)

Synonym
thp(a)
(4s,5s)-2-methyl-4-carboxy-5-hydroxy-3,4,5,6-tetrahydropyrimidine
hydroxyectoine
CHEMBL1230488
beta-hydroxyectoine
(s,s)-2-methyl-5-hydroxy-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid
4-pyrimidinecarboxylic acid, 1,4,5,6-tetrahydro-5-hydroxy-2-methyl-, (4s,5s)-
CHEBI:49432 ,
5-hydroxyectoine
(4s,5s)-5-hydroxy-2-methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid
6cs ,
165542-15-4
ronacare hydroxyectoin
hydroxyectoin
pyrostatin a
(s,s)-1,4,5,6-tetrahydro-5-hydroxy-2-methyl-4-pyrimidinecarboxylic acid
unii-cij7yn252e
4-hydroxy-imino-1-methylpyrrolidone-5-carboxylic acid
cij7yn252e ,
4-pyrimidinecarboxylic acid, 1,4,5,6-tetrahydro-5-hydroxy-2-methyl-, (s-(r*,r*))-
(s,s)-beta-hydroxyectoine
AKOS015911339
(s,s)-.beta.-hydroxyectoine
hydroxyectoin [inci]
.beta.-hydroxyectoine
SCHEMBL748472
SCHEMBL15281462
hydroxyectoine, primary pharmaceutical reference standard
DTXSID80167963
4-pyrimidinecarboxylicacid,1,4,5,6-tetrahydro-5-hydroxy-2-methyl-,(4s,5s)-
hydroxyectoine, >=95% (hplc)
J-010208
(5s,6s)-5-hydroxy-2-methyl-1,4,5,6-tetrahydropyrimidine-6-carboxylic acid
Q27121627
(s,s)--hydroxyectoine; 5-hydroxyectoine; pyrostatin a; pyrostatine a; -hydroxyectoine
(4s,5s)-5-hydroxy-2-methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylicacid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Considering that ectoine and hydroxyectoine are not toxic to cellular environment even at concentrations as high as 100 mM, the results may suggest a basis for the development of ectoines as potential inhibitors associated with neurodegenerative diseases."( Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer's beta-amyloid.
Kanapathipillai, M; Lentzen, G; Park, CB; Sierks, M, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (5)

ClassDescription
iminium betaine
carboxamidineCompounds having the structure RC(=NR)NR2. The term is used as a suffix in systematic nomenclature to denote the -C(=NH)NH2 group including its carbon atom.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
1,4,5,6-tetrahydropyrimidinesAny tetrahydropyrimidine in which the double bond is between positions 1 and 2.
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1230184Toxicity in Wistar rat assessed as decrease in Hsp70 level at 50 to 300 mg/kg, po qd administered for 1 week starting 48 hrs post TNBS induction by ELISA2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230164Anti-colitis activity in Wistar rat assessed as suppression of TNBS-induced body weight reduction at 50 to 300 mg/kg, po qd administered for 1 week starting 48 hrs post TNBS induction2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230178Anti-colitis activity in Wistar rat assessed as suppression of TNBS-induced colonic IL-1beta level at 50 to 100 mg/kg, po qd administered for 1 week starting 48 hrs post TNBS induction by ELISA2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230177Anti-colitis activity in Wistar rat assessed as suppression of TNBS-induced colonic TNF-alpha level at 50 to 100 mg/kg, po qd administered for 1 week starting 48 hrs post TNBS induction by ELISA2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230181Anti-colitis activity in Wistar rat assessed as suppression of TNBS-induced fecal calprotectin level at 100 mg/kg, po qd administered for 1 week starting 48 hrs post TNBS induction by ELISA2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230174Anti-colitis activity in Wistar rat assessed as suppression of TNBS-induced reduction of colonic GSH level at 50 to 300 mg/kg, po qd administered for 1 week starting 48 hrs post TNBS induction by spectrophotometric analysis2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230188Toxicity in Wistar rat assessed as effect on myeloperoxidase activity at 100 mg/kg, po qd administered for 1 week by spectrophotometric analysis2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230182Toxicity in Wistar rat assessed as decrease in Hsp70 level at 100 mg/kg, po qd administered for 1 week by ELISA2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230187Toxicity in Wistar rat assessed as effect on colon mass index at 100 mg/kg, po qd administered for 1 week2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230179Toxicity in Wistar rat assessed as effect on colonic ICAM1 level at 100 mg/kg, po qd administered for 1 week by ELISA2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230166Anti-colitis activity in Wistar rat assessed as reduction of TNBS-induced ulcerative area at 50 to 300 mg/kg, po qd administered for 1 week starting 48 hrs post TNBS induction (Rvb = 4.9 cm2)2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230172Toxicity in Wistar rat assessed as effect on colonic GSH level at 100 mg/kg, po qd administered for 1 week by spectrophotometric analysis2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230171Anti-colitis activity in Wistar rat assessed as reduction of TNBS-induced myeloperoxidase activity at 50 mg/kg, po qd administered for 1 week starting 48 hrs post TNBS induction by spectrophotometric analysis2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230186Toxicity in Wistar rat assessed as effect on body weight at 100 mg/kg, po qd administered for 1 week2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230190Toxicity in Wistar rat assessed as effect on IL-1beta level at 100 mg/kg, po qd administered for 1 week by ELISA2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230189Toxicity in Wistar rat assessed as effect on TNF-alpha level at 100 mg/kg, po qd administered for 1 week by ELISA2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
AID1230168Anti-colitis activity in Wistar rat assessed as reduction of TNBS-induced colon mass index at 50 mg/kg, po qd administered for 1 week starting 48 hrs post TNBS induction (Rvb = 7.9 mg/g)2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (80)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (3.75)18.2507
2000's28 (35.00)29.6817
2010's42 (52.50)24.3611
2020's7 (8.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.12 (24.57)
Research Supply Index4.43 (2.92)
Research Growth Index5.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.20%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other82 (98.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]